Synthesis and antiemetic activity of 1,2,3,9-tetrahydro-9-methyl-3-(4-substituted-piperazin-1-ylmethyl)-4
Qigui XU, Tianyu LIU, Rui TIAN, Qingeng LI, Deyin MA
Synthesis and antiemetic activity of 1,2,3,9-tetrahydro-9-methyl-3-(4-substituted-piperazin-1-ylmethyl)-4
5-HT3 receptor antagonists, such as Ondansetron, are used for anti-emesis after chemotherapy, radiotherapy and operations. Some Ondansetron analogs possessing piperazine ring as side chains were synthesized in our lab. Thus, one of the two carbonyl groups of starting material 1,3-cyclohexandione (1) was condensed with phenylhydrazine hydrochloride to form monophenylhydrazone (2). 1,2,3,9-Tetrahydro-4H-carbazol-4-one (3) was prepared from 2via cyclization and rearranged in the presence of ZnCl2. Through a methylation reaction, compound 3 was converted to 1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one (4). 3-Dimethylaminomethyl substituted compound (5) was synthesized from 4 by a Mannich reaction in glacial acetic acid. Nine novel 1,2,3,9-tetrahydro-9-methyl-3-(4-substituted-piperazin-1-ylmethyl)- 4H-carbazol-4-one derivatives (6a-6i) were synthesized through nucleophilic substitution reaction of 5 with piperazines. The structures of all the target compounds were determined by elemental analysis, IR, MS, 1H NMR and 13C NMR spectra. The results of preliminary pharmacological test show that part of the novel compounds have antiemetic activity comparable to that of the control Ondansetron.
5-HT3 receptor antagonist / 1 / 2 / 3 / 9-tetrahydro-4H-carbazol-4-one / Mannich reaction / antiemetic
[1] |
Milne R J, Heel R C. Ondansetron: therapeutic use as an antiemetic. Drugs, 1991, 41(4): 574-595
CrossRef
Google scholar
|
[2] |
Markham A, Sorkin E M. Ondansetron: an update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting. Drugs, 1993, 45(6): 931-952
CrossRef
Google scholar
|
[3] |
Wilde M I, Markham A. Ondansetron: a review of its pharmacology and preliminary clinical findings in novel applications. Drugs, 1996, 52(5): 773-794
|
[4] |
Kohler D R, Goldspiel B R. Ondansetron: a serotonin receptor (5-HT3) antagonist for antineoplastic chemotherapy-induced nausea and vomiting. DICP, 1991, 25(4): 367-380
|
[5] |
Roberson C R, McLeskey C H. Ondansetron: in a class (5-HT3) of its own. Semin Anesth, 1996, 15 (1): 41-46
CrossRef
Google scholar
|
[6] |
Culy C R, Bhana N, Plosker G L. Ondansetron: A review of its use as an antiemetic in children. Paediatr Drugs, 2001, 3(6): 441-479
CrossRef
Google scholar
|
[7] |
Hilbert M F, Hoffmann R, Miller R C, Carr A A. Conformation-Activity Relationship study of 5-HT3 receptor antagonists and a definition of a model for this receptor site. J Med Chem, 1990, 33(6): 1594-1600
CrossRef
Google scholar
|
[8] |
Clemo G R, Felton D G I. The Chemistry of the Carbazoles:1,2,3,4-Tetrahydro-4-ketocarbazoles. J Chem Soc, 1951, 700-702
CrossRef
Google scholar
|
[9] |
Oikawa Y, Yonemitsu O. Selective oxidation of the side chain at C-3 of indoles. J Org Chem, 1977, 42: 1213-1246
CrossRef
Google scholar
|
[10] |
Chen G H. Synthesis of antiemetic ondansetron. Chin J Pharm, 1993, 24(6): 241-242 (in Chinese)
|
[11] |
Mongolsuk S, Robertson A, Towers R. 2,4,3',5'-Tetrahydroxystilbene from Artocarpus lakoocha. J Chem Soc, 1957, 2231-2233
CrossRef
Google scholar
|
[12] |
Littell R, Greenblatt E N, Allen G R. Mannich bases of 2,3-dihydro-4(1H)-carbazolones as potential psychotropic agents. J Med Chem, 1972, 15(8), 875-876
CrossRef
Google scholar
|
[13] |
Bermudez J, Boyle E A, Miner W D, Sanger G J. The anti-emetic potential of the 5-hydroxytryptamine 3 receptor antagonist BRL 43694. Br J Cancer, 1988, 58(5): 644-650
|
[14] |
Stables R, Andrews P L R, Bailey H E, Costall B, Gunning S J, Hawthorn J, Naylor R J, Tyers M B. Antiemetic properties of the 5-HT3 receptor antagonist, GR 38032F. Cancer Treat Rev, 1987, 14: 333-336
CrossRef
Google scholar
|
[15] |
Littell R, Allen G R. 3-(Morpholinomethyl)-2,3-dihydrocarbazol-4(1H)-ones. <patent>US 3634420</patent>, 1972 [Chem Abstr, 1972, 76, 72400]
|
[16] |
Kuang Y Q, Zhang S Y, Sun X L. Synthesis of 1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one. Chin J Pharm, 1994, 25(1): 36-37 (in Chinese)
|
[17] |
Maikeru B T. Medicine. <patent>J P 63165314</patent>, 1988 [Chem Abstr, 1989, 110, 205704]
|
[18] |
Coates I H, Bell J A, Humber D C, Ewan G B. 3-Imidazolylmethyl-1,2,3,9-tetrahydro-4H-carbazol-4-one derivatives. <patent>DE 3502508</patent>, 1985 [Chem Abstr, 1986, 104, 19589]
|
[19] |
Zinnes H. Process for the preparation of 4-keto-1,2,3,4-tetrahydrocarbazole. <patent>US 3892766</patent>, 1975 [Chem Abstr, 1975, 83, 178814]
|
[20] |
Lu J R, Shi X Z. Synthesis of Ondansetron Hydrochloride. J China Pharm Univ, 1999, 30(4): 246-248 (in Chinese)
|
/
〈 | 〉 |